IBI310 (Anti-CTLA-4) in Combination With Sintilimab in Patients With Non-small-cell Lung Cancer (NSCLC)
Clinical trial NCT05118334 · COMPLETED
Trial details
- NCT number
- NCT05118334
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-11-12
- Primary completion
- 2022-07-31
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.